Organogenesis (ORGO) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Organogenesis (NASDAQ:ORGO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership, community ranking and valuation.

Does the MarketBeat Community prefer RXRX or ORGO?

Organogenesis received 67 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 65.99% of users gave Organogenesis an outperform vote while only 55.56% of users gave Recursion Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Recursion Pharmaceuticals	Outperform Votes 30 55.56%	Underperform Votes 24 44.44%
Organogenesis	Outperform Votes 97 65.99%	Underperform Votes 50 34.01%

Does the media refer more to RXRX or ORGO?

In the previous week, Recursion Pharmaceuticals had 7 more articles in the media than Organogenesis. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 2 mentions for Organogenesis. Recursion Pharmaceuticals' average media sentiment score of 0.48 beat Organogenesis' score of 0.37 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organogenesis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, RXRX or ORGO?

Recursion Pharmaceuticals has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500.

Do analysts rate RXRX or ORGO?

Recursion Pharmaceuticals presently has a consensus price target of $8.25, indicating a potential upside of 55.95%. Organogenesis has a consensus price target of $5.50, indicating a potential upside of 26.44%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is RXRX or ORGO more profitable?

Organogenesis has a net margin of -1.62% compared to Recursion Pharmaceuticals' net margin of -579.52%. Organogenesis' return on equity of -2.69% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-579.52%	-76.56%	-55.68%
Organogenesis	-1.62%	-2.69%	-1.63%

Do institutionals and insiders believe in RXRX or ORGO?

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 15.8% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 36.9% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has preferable earnings & valuation, RXRX or ORGO?

Organogenesis has higher revenue and earnings than Recursion Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.49M	36.36	-$328.07M	-$1.66	-3.19
Organogenesis	$482.04M	1.14	$4.95M	-$0.02	-217.50

Summary

Organogenesis beats Recursion Pharmaceuticals on 11 of the 18 factors compared between the two stocks.